Introduction
Amino acid immunocytochemistry is based on the simple concept that free amino acids can be made immunogenic by coupling them to carrier proteins by means of glutaraldehyde [ 1, 2] . Antibodies raised against such conjugates can be used in immunocytochemical studies of glutaraldehyde-fixed tissue [l-61. The glutaraldehyde fixation serves a dual purpose: it secures an optimum preservation of ultrastructure, and retains a substantial amount of the free amino acids in a form that can be recognized by the specific antibodies.
When glutamate antibodies became available and were applied to sections of perfusion-fixed rat brains, it was soon realized that the immunoreactivity was widely distributed at the regional as well as the cellular level [ 3 ] . This came as no surprise, as biochemical analyses had revealed only modest variations in glutamate contents between different brain regions [7] . The uniformly high concentration of glutamate was thought to reflect the widespread occurrence of glutamatergic synapses, as well as the presence of considerable pools of non-transmitter, 'metabolic', glutamate. Attempts to calculate the proportion of brain glutamate that resides in glutamate-releasing terminals had given values as low as 20-45% [8] , implying that non-transmitter glutamate predominates quantitatively. Non-transmitter glutamate includes precursor glutamate for y-aminobutyric acid (GABA), and glutamate involved in the general metabolism and protein synthesis in neurons and glia.
It was obvious that a biologically meaningful interpretation of glutamate-immunolabelled preparations required that distinctions be made between the different glutamate pools. Specifically, the need arose to identify the pool of glutamate actually available for synaptic release (hereafter defined as the transmitter pool). This was deemed of particular importance considering the lack of definitive histological markers for glutamatergic synapses.
Our original immunocytochemical analyses were based on standard light microscopic, peroxidase-antiperoxidase methods [ 31. W e assumed that the interpretation of the glutamate immunolabelling would be much facilitated by switching to electron microscopic, postembedding immunogold procedures, which afford a high anatomical resolution combined with possibilities of quantitation [ 91.
We have based most of our studies on a twostep immunogold procedure [ 10, 1 13, The primary antibody is applied directly onto an ultrathin section (obtained from brains embedded in an epoxy resin), followed by a secondary antibody coupled to colloidal gold particles. The anatomical resolution of this procedure is limited only by the combined size of the two immunoglobulin molecules that are interposed between the antigen and gold particle [ 1 11 . Quantitation is achieved by computer-assisted calculation of the areal density of gold particles [ 121.
The biological relevance of this quantitative approach is secured by the strictly superficial labelling of the ultrathin sections [9] other tissue elements [ 10-181. Typically, in perfusion-fixed materials, glutamatergic terminals display a two-threefold higher gold particle density than tissue average (corresponding to a concentration of fixed glutamate of up to 30 mmol/l [13] ), and a four-fivefold higher density than profiles of glial processes and presumed GABAergic terminals. A similar pattern is found in organotypic slice cultures ( Figure 1 ) [ 191. Glutamatergic neurones are further characterized by the presence of an intracellular gradient of glutamate, with a higher concentration in the nerve terminal than in the cell body [18] . The latter observation could reflect the sequestration of glutamate in synaptic vesicles [20] . An association of glutamate-like immunoreactivity with synaptic vesicles has been verified by determining the relationship between gold particle density and packing density of synaptic vesicles ([ 171; see also [ 151) . (This must be carried out in preparations that are more strongly immunolabelled than that in Figure 1 .) For example, spinocerebellar mossy fibre terminals show a highly significant positive correlation ( r = 0.94) between these two parameters [ 171).
The association of glutamate-like immunoreactivity with synaptic vesicles is particularly evident in the giant reticulospinal axons of lamprey (Zchtyomyzon unzcuspzi), which show a clear spatial segregation between the different subcellular compartments. In these axons the particle density over vesicle clusters is about 15 times higher than that over axoplasmic matrix [21] . The labelling density suggests an intravesicular glutamate concentration of about 60 mmol/l, which is in good accordance with biochemical analyses in other species [20] .
High resolution, quantitative immunocytochemistry can thus be used to identify a glutamate pool that is enriched in certain populations of nerve terminal and associated with synaptic vesicles. To verify that this pool corresponds to the transmitter pool, we investigated whether it could be depleted under conditions that are known to induce synaptic release. Exposure of cerebellar [22] or hippocampal [23] slices to a high K f concentration (40-55 mmol/l) decreased the nerve-terminal labelling by 25-90%, depending on the severity of depolarization and the glutamatergic fibre system under study. The effect was partially dependent on Ca2+, suggesting that the depletion was due to exocytosis and was not simply caused by a reversal of the glutamate carrier in the presynaptic membrane [24] . The depolarization with high K+ did not lead to a depletion of glutamate-like immunoreactivity from nonterminal portions of the neurons (such as postsynaptic spines), and was associated with an increased immunolabelling of astrocytes (reflecting glial reuptake of released glutamate).
The latter type of experiment provides a means of studying glutamate release from identified nerve terminals in preparations with an intact anatomical organization.
Non-transmitter pools of glutamate
Although astrocytes are equipped with a glutamate uptake carrier [8] they show a low level of glutamate-like immunoreactivity (Figures 1 and 2) [ 10, 111. This is in agreement with biochemical data pointing to a rapid metabolism of glutamate in glia Volume 
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Excitatory Amino Acids [ Z ] . Glutamine synthetase is an important enzyme in this regard. It converts glutamate to glutamine, and is restricted to glial cells [26] . Glutamine formed in glia is believed to be transferred back to the glutamatergic nerve terminals to act as a precursor of glutamate through the action of phosphate-activated glutaminase [25] .
The existence of such a metabolic compartmentation receives morphological support from preparations double-labelled for the visualization of glutamate and glutamine (Figures 1 and 3) [27] .
While glutamate is enriched in certain nerve-terminal populations compared with glial cells, the converse is true for glutamine (Figure 2 ). In the organotypic slice culture [28] shown here (Figures  1 and 2) , the ratio between the respective immunolabelling densities (g1utamate:glutamine ratio) was more than 100 times higher in the nerve terminals (terminals establishing asymmetric contacts with dendritic spines in CA1) than in astrocytes. A similar but less differentiated pattern was found in material from perfusion-fixed rat cerebellum [27] .
Interestingly, the g1utamate:glutamine ratio in hippocampal glial cells was much increased after 20 min of forebrain ischaemia [29] (R. Torp et al., unpublished work), suggesting that the capacity of glial cells to metabolize glutamate is impaired in this condition. This agrees with the ATP-dependency of glutamine synthetase [25] . A metabolic block in the glial cells could contribute to the accumulation of extracellular glutamate in the ischaemic brain.
As mentioned above, presumed GABAergic terminals typically show a level of glutamate immunolabelling corresponding to one fifth to one quarter of that in glutamatergic terminals. In a recent study of the suprachiasmatic nucleus (M.
Castel, M. Belenky, S. Cohen, 0. P. Ottersen and J.
Storm-Mathisen, unpublished work), the glutamate immunolabelling density of GABA-immunopositive terminals was found to be about twice as high as that in non-glutamatergic, non-GABAergic (Glu -/ GAI3A-) terminals. This suggests that at least 50% of the glutamate that is present in these GABAergic terminals represents a genuine precursor pool (assuming that the labelling intensity of Glu-1 GABA-terminals corresponds to the size of the general metabolic pool). The different particle density values between the GABA-immunopositive and Glu-1G-Aterminals mainly reflected a more intense mitochondrial labelling in the former population. The high concentration of glutamate in mitochondria of GABAergic terminals is compatible with the mitochondria1 localization of phosphateactivated glutaminase and the important role of glutamine as an indirect precursor of GABA [30] .
As expected, both types of non-glutamatergic terminal failed to show an accumulation of glutamateimmunolabelling over vesicle clusters.
Conclusion
In immunocytochemical preparations, different glutamate pools can be identified by virtue of their enrichment in specific subcellular compartments and organelles, their coexistence with other amino acids (e.g. glutamine and GABA) and their sensitivity to depolarization. This approach offers the possibility of studying the metabolism and synaptic handling of neurotransmitter amino acids in preparations with preserved structural integrity. Organotypic slice cultures should be well suited as a model system for such studies. 
Introduction
Studies in brain tissue preparations of the incorporation of radioactivity from different "C-labelled precursors (glucose, acetate and bicarbonate) into glutamate and glutamine have shown clearly that glutamate metabolism is extremely complicated [ 11.
Glutamine was found to attain a much higher specific radioactivity than its precursor glutamate and therefore two or more metabolically distinct pools of glutamate were envisaged, each being metabolized to glutamine with different turnover rates. Moreover, it was suggested that these pools could represent different cell types and it was predicted that glutamine synthesis from glutamate would be particularly prominent in one of these pools which in all likelihood would be localized in glial cells rather than in neurons. That this is indeed the case was firmly established with the elegant demonstration by Norenberg and Martinez-Hernandez [Z] that the glutamine-synthesizing enzyme glutamine synthetase is localized in astrocytes and not in neurons. As a consequence of this there must be a cycling of glutamate and glutamine between neurons and astrocytes and this cycling has been Abbreviations used: AAT, aspartate aminotransferase; GABA, y-aminobutyric acid; TCA, tricarboxylic acid. defined as the glutamate/glutamine cycle [3, 41.
During recent years it has become apparent that other amino acids and tricarboxylic acid cycle (TCA) constituents should also be considered as likely precursors for neurotransmitter glutamate [ 51.
The development of primary cultures of glutamatergic neurons and of astrocytes separately or in co-culture [6-91 has made it possible to study transmembrane fluxes as well as the biochemical conversions of glutamate and its precursors in the individual cell types. These studies have allowed a quantitative assessment of these parameters to be made [5, lo] . This review will provide an overview of the current status of knowledge about transmembrane fluxes of glutamate and some of its precursors as well as their apparent metabolic interconversions.
Transmem brane fluxes
Glutamate/glutamine On the basis of a large number of studies of glutamate uptake into primary cultures of glutarnatergic neurons and astrocytes from different brain areas (see [ 111) it can be concluded that the rate of astrocytic glutamate uptake is higher than the neuronal uptake rate. This is illustrated in Figure 1 which shows glutamate uptake into the two cell types at an
